China’s All-Out Push to Overtake US in Drug Development
Using AI and DNA from 33,000 children.
This article is for subscribers only.
Welcome back to Bloomberg’s Health Monitor, a weekly look at the boardroom decisions, scientific advances and policy fights shaping the future of medicine. Sign up now if you’re not already on the list.
Earnings are starting to roll in, with drugmakers posting big gains on treatments for cancer, Alzheimer’s disease and psoriasis. But European access to new medicines is on the decline. Hospitals and some insurers are also starting to suffer as US cost-cutting efforts start to pinch.